Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02429492
Other study ID # C14-21
Secondary ID 2014-A01240-47
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date November 16, 2015
Est. completion date November 2021

Study information

Verified date August 2021
Source Institut National de la Santé Et de la Recherche Médicale, France
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Amyotrophic lateral sclerosis (ALS) is due to neurodegeneration of upper and lower motor neurons, leading to muscle atrophy, paralysis and death. However, there is growing evidence that interneurons involved in the gain regulation of spinal motoneuron (lower motor neurons) and in sensorimotor integration may participate in the pathogenesis of ALS. While sensory afferents in the peripheral nerve are traditionally thought to be unaffected at the beginning of the disease, diffusion MRI has revealed degeneration and demyelination of the posterior columns in the spinal cord of patients recently diagnosed with ALS, and there are sporadic reports of sensory involvement. Early alteration of the sensorimotor integration could participate to the degeneration of motor neurons and interneurons. The goal of the project is to further investigate sensorimotor integration at spinal level in human patients recently diagnosed with ALS, and to study whether an interneuron pathology could participate in ALS pathogenesis. Our project has first an interest for the fundamental research aiming at increasing basic knowledge of pathophysiology of ALS, and specifically on the functional effects of the underlying neurodegenerative mechanisms. By testing the excitability of spinal interneurons in patients recently diagnosed, and by doing so for clinically uninvolved muscles, we will be able to evaluate whether an interneuron pathology could be involved in ALS. Our results will help to understand better the chain reactions in the neurodegenerative processes that dramatically evolve until the death of all motor neurons. Our project has also an interest for the development of therapeutic approaches for ALS. Indeed, our methods will help to determine specific electrophysiological biomarkers that will help to evaluate quantitatively spinal and corticospinal neural processes: their changes during the course of the disease (follow-up study), the effect of therapeutic agents and/or rehabilitation methods on their excitability, and their repercussions on motor neuron activity (evaluation of therapeutics). Lastly, our methods could be tested in other neuromuscular diseases to determine possible differences in spinal neural activity. Indeed, the motor dysfunction common to several neuromuscular diseases can make it difficult to make a definitive diagnosis. The development of specific biomarkers is crucial for an early diagnosis, and to evaluate the best treatment for the patients as rapidly as possible.


Description:

Given the all-or-none properties of neuromuscular junctions, the electromyogram (EMG) reflects the activity of spinal motoneurons. These neurons are the last order neurons in all neural pathways involved in motor control. Modification of the afferent neural activity, whatever its level (spinal or supraspinal), will affect the excitability of spinal motoneurons and thus EMG activity. Combined with electrical and/or magnetic stimulation of peripheral nerve and/or cortical structures, it is possible to test indirectly the excitability of corticospinal and spinal reflex pathways involved in human motor control. One of the novelties is that we will investigate the interneurons that are activated by motor axons or afferents inputs from affected muscles (distal musculature: hand/wrist or foot/ankle muscles), which control clinically unaffected muscles (proximal musculature: elbow or knee muscles). This has a threefold interest i) functional exploration of clinically unaffected muscles that are never evaluated in ALS patients, ii) to better interpret the EMG signal and to better elucidate the pathophysiological mechanisms underlying the change in EMG activity, and iii) to determine if interneuron pathology manifests before detectable change in the motoneuron. The conditioned EMG and threshold tracking methods will be used to evaluate the excitability of spinal interneurons in ALS patients, as compared to sex and age-matched healthy subjects.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 120
Est. completion date November 2021
Est. primary completion date September 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 80 Years
Eligibility Inclusion Criteria: - speaking french - signature of the written consent - patients with ALS and no other motor neuron disease (ALS group) - neurologically intact subjects (Control group) Exclusion Criteria: - pregnancy - contraindication to TMS

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Electrophysiology
EMG recordings conditioned by electrical peripheral nerve stimulation and/or transcranial magnetic stimulation

Locations

Country Name City State
France Hopital Pitie Salpetriere Paris

Sponsors (1)

Lead Sponsor Collaborator
Institut National de la Santé Et de la Recherche Médicale, France

Country where clinical trial is conducted

France, 

References & Publications (1)

Turner MR, Kiernan MC. Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis? Amyotroph Lateral Scler. 2012 May;13(3):245-50. doi: 10.3109/17482968.2011.636050. Epub 2012 Mar 16. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Excitability of spinal neurons Electromyogram (EMG) reflects the activity of spinal motoneurons which is controlled by several spinal interneurons. EMG recordings will be conditioned by electrical, magnetic or mechanical stimuli to activate spinal interneurons that controlled motoneurons and thus influence the EMG recordings. The resulting changes in EMG activity will be quantified by calculating the EMG surface area or the change in peak-to-peak amplitude of evoked potentials. 2 visits will be devoted to cervical interneurons controlling upper limbs and the 2 other visits, to lumbar interneurons controlling lower limbs. Surface areas and amplitude in ALS patients will be compared to controls The participants will be invited to 4 sessions of EMG recordings whose duration will be of 2h30, within the month after inlcusion for ALS patients and within the year after inclusion for the healthy subjects
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04948645 - A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis Phase 1
Completed NCT02405182 - MRI Biomarkers in ALS
Completed NCT00696332 - Talampanel for Amyotrophic Lateral Sclerosis (ALS) Phase 2
Recruiting NCT03865420 - Amyotrophic Lateral Sclerosis (ALS) Families Project
Terminated NCT04054141 - rTMS in Treatment of Spasticity N/A
Recruiting NCT03272503 - A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Completed NCT05568615 - Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS Phase 3
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Active, not recruiting NCT04259255 - Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
Recruiting NCT02495571 - Assessment of Voluntary and Reflex Cough in Patients With ALS N/A
Completed NCT02525471 - A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS) Phase 1
Recruiting NCT05031351 - NF-κB Inhibition in Amyotrophic Lateral Sclerosis Phase 2
Active, not recruiting NCT05581771 - Factors Associated With Success of NIPPV in ALS Patients
Active, not recruiting NCT03268603 - Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS) Phase 2
Recruiting NCT05271435 - Digital Tools for Assessment of Motor Functions and Falls in ALS
Completed NCT06005506 - National Multicenter Interventional Study Aimed at Evaluating the Effect on the Intestinal Microbiota in Chronically Frail Patients Who Share Alterations in Intestinal Function. N/A
Recruiting NCT04138095 - Virtual Reality as an Adjunct to Management of Pain and Anxiety in Palliative Care N/A
Recruiting NCT03698149 - ECoG BMI for Motor and Speech Control N/A
Not yet recruiting NCT05621213 - Satisfaction of Patients With Amyotrophic Lateral Sclerosis Regarding Home Assisted Teleconsultation N/A
Terminated NCT03373981 - Non-invasive Brain Stimulation for the Treatment of Depression Symptoms in ALS N/A

External Links